Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)

Fig. 1

Intervention Scheme. Patients with PD after two cycles of induction treatment, PD or SD after four cycles, insufficient bone marrow recorvery after chemotherapy or insufficient stem cell harvest are not eligible for randomization; patients with complete remission, unconfirmed complete remission or partial remission after completion of therapy will undergo regular follow up; patients with stable disease or progressive disease after completion of therapy will undergo salvage treatment according to investigator’s choice. PCNSL = primary central nervous system lymphoma; ECOG = Eastern Cooperative Oncology Group Performance Status; d = day; MTX = methotrexate; AraC = cytarabine; HDT-ASCT = high-dose chemotherapy followed by autologous stem cell transplantation; BCNU = carmustine,** if BCNU is not available at study site, busulfan can be used instead; PD = progressive disease; SD = stable disease; PR = partial remission; CR = complete remission; uCR = unconfirmed complete remission

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us